Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last A$0.03 AUD
Change Today 0.00 / 0.00%
Volume 0.0
QRX On Other Exchanges
Symbol
Exchange
Berlin
OTC US
OTC US
As of 2:16 AM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

100 Walker Street

Level 11

Suite 1

North Sydney, NSW 2060

Australia

Phone: 61 2 8404 4139

Fax: 61 2 8920 0314

QRxPharma Limited operates as a clinical-stage specialty pharmaceutical company that focuses on the development and commercialization of new treatments for pain management and central nervous system (CNS) disorders in Australia. The company's product portfolio includes both late and early stage clinical drug candidates. It intends to directly commercialize its products in the U.S. and seek strategic partnerships for worldwide markets. Products The company’s preclinical and clinical pipeline includes other technologies in the fields of pain management, neurodegenerative disease, and venomics. The company's primary compound, MoxDuo IR (Q8003IR), is in Phase 3 clinical development and has completed multiple comparative studies evaluating its efficacy and safety against equianalgesic doses of morphine, oxycodone, and Percocet for the treatment of acute pain. The company's Dual-Opioid product portfolio includes two complementary products: MoxDuo CR, a controlled-release oral capsule (with abuse deterrent and tamper resistant technologies) for chronic pain; and MoxDuo IV, an intravenous formulation for treating moderate to severe hospital-based pain. The company intends to initiate a Phase 2 comparative proof-of-concept study evaluating the efficacy and safety of MoxDuo IV (an intravenous morphine plus oxycodone formulation) against IV morphine for the treatment of moderate to severe post-operative pain. It also intends to initiate its Phase 1 study of MoxDuo CR, a continuous release Dual-Opioid. Additionally, the company is advancing the development of its Torsin program under collaborative research agreement with the University of Alabama (Caldwell Labs). These small molecules target dystonia, Parkinson’s disease, and Alzheimer’s disease, as well as similar neurologic disorders. Preclinical trials are underway to evaluate the company’s drug candidates in Parkinson’s disease. Agreements The company has a collaborative research agreement with the University of Queensland for the conduct of the Australian Research Council linkage project grant of ‘pre-clinical evaluation of snake venom proteins with therapeutic potential’.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
QRX:AU A$0.03 AUD 0.00

QRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for QRX.
View Industry Companies
 

Industry Analysis

QRX

Industry Average

Valuation QRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 40.8x
Price/Book 0.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact QRXPHARMA LTD, please visit www.qrxpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.